| Título: | A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital |
| Autores: |
Chin, S. N. Wang, L. Moore, M. Sridhar, S. S.; University of Toronto |
| Fecha: | 2010-03-31 |
| Publicador: | Multimed Inc. |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | ABSTRACTBackgroundBased on the tax 327 phase iii trial, docetaxel-based chemotherapy is the standard first-line treatment for hormone-resistant prostate cancer (hrpc); however, there is some heterogeneity in the use of this agent in routine clinical practice. The aim of the present study was to examine the patterns of docetaxel use in routine clinical practice at our institution and to compare them with docetaxel use in the tax 327 clinical trial.MethodsWe conducted a retrospective chart review of hrpc patients treated with first-line docetaxel between 2005 and 2007 at the Princess Margaret Hospital.ResultsIn the first-line setting, 88 patients with hrpc received docetaxel. The main reasons for initiating docetaxel were rising prostate-specific antigen (psa, 98%) and progressive symptoms (77%). The psa response rate was 67%; median time to response was 1.5 months, and duration of response was 6.8 months. Median survival was 15.9 months (95% confidence interval: 12.4 to 20.5 months). Patients received a median of 7 cycles of treatment, and the main toxicities were fatigue (35%) and neuropathy (24%). Post docetaxel, 36 patients received second-line treatment with a 22% response rate.ConclusionsIn routine clinical practice, hrpc patients received docetaxel mainly because of symptomatic disease progression. Overall response rates and toxicities were comparable to those in the tax 327 trial. However, our patients received a median of only 7 cycles of treatment versus the 9.5 administered on trial, and survival was slightly shorter in our single-institution study. A larger prospective multicentre analysis, including performance status and quality-of-life parameters, may be warranted to determine if docetaxel performs as well in routine clinical practice as it does in the clinical trial setting. |
| Idioma: | Inglés |
1 Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind por Sagar, Stephen,Dryden, Trish; Centre for Applied Research, Centennial College,Wong, Raimond K; McMaster University, Departments of Medicine and Oncology | 6 Cord stem-cell transplantation in Ontario: do we need a public bank? por Gassas, A.; the Hospital for Sick Children, Toronto |
2 Chinese Medicine and Biomodulation in Cancer Patients (Part Two) por Sagar, Stephen M,Wong, Raimond K | 7 Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis por Szwajcer, D.; University of Manitoba,Czaykowski, P.; University of Manitoba,Turner, D.; CancerCare Manitoba |
3 Integrating Science and Human Values for Cancer Patient Care por Sutcliffe, Simon B.; BC Cancer Agency | 8 Liver transplantation for symptomatic liver metastases of neuroendocrine tumours por Chan, G.; Hôpital Maisonneuve-Rosemont
Université de Montréal,Kocha, W.,Reid, R.,Taqi, A.,Wall, W.,Quan, D. |
4 Conservative Treatment of Invasive Bladder Cancer por Souhami, Luis; McGill University,Rene, Nicholas,Cury, Fabio Biagini | 9 What is the optimal management of dysphagia in metastatic esophageal cancer? por Cavallin, F.; Veneto Institute of Oncology,Scarpa, M.; Veneto Institute of Oncology,Cagol, M.; Veneto Institute of Oncology,Alfieri, R.; Veneto Institute of Oncology,Castoro, C.; Veneto Institute of Oncology |
5 | 10 Responses by breast and prostate cancer patients to out-of-pocket costs in Newfoundland and Labrador por Housser, E.; Newfoundland and Labrador Centre for Health Information,Mathews, M.; Memorial University,LeMessurier, J.; Memorial University,Young, S.; Memorial University,Hawboldt, J.; Memorial University,West, R.; Memorial University |